<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03832140</url>
  </required_header>
  <id_info>
    <org_study_id>PRURIGAMMA (29BRC18.0192)</org_study_id>
    <nct_id>NCT03832140</nct_id>
  </id_info>
  <brief_title>Frequency and Characteristics of Pruritus in Patients With Monoclonal Gammopathy</brief_title>
  <acronym>PRURIGAMMA</acronym>
  <official_title>Frequency and Characteristics of Pruritus in Patients With Monoclonal Gammopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pruritus is most often secondary to dermatitis but can also occur without skin lesions, it is
      called pruritus sine materia. The causes of pruritus sine materia are various: haematological
      (myeloproliferative neoplasia ...), hepatic (cholestasis ...), renal (chronic renal failure,
      dialysis), endocrine (iron deficiency ...), secondary to drug intake ... or idiopathic when
      no cause is found.

      Gammapathies are among the causes of pruritus sine materia, and as such electrophoresis of
      serum proteins is usually part of the pruritus assessment to look for monoclonal gammopathy
      (MGUS, multiple myeloma, Waldenstr√∂m disease). However, there is very little data on the
      frequency of pruritus in patients with monoclonal gammopathy and the characteristics of this
      pruritus. So the aim of this study is to compare the frequency of pruritus between patients
      with monoclonal gammapathy and controls
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 24, 2019</start_date>
  <completion_date type="Anticipated">November 24, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 24, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of pruritus</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">470</enrollment>
  <condition>Pruritus</condition>
  <condition>Monoclonal Gammopathy</condition>
  <arm_group>
    <arm_group_label>Patients with monoclonal gammopathy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with a normal plasma protein electrophoresis</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who had serum protein electrophoresis at Brest CHRU between 2014 and 2017, with
        and without gammapathy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for case :

        Major patient Realized Serum protein electrophoresis between 2014 and 2017 Hematology
        follow-up at Brest CHR Positive monoclonal gammopathy Non-opposition formulated

        Inclusion Criteria for Control :

        Major patient Realized Serum protein electrophoresis between 2014 and 2017 Hematology
        follow-up at Brest CHR Negative gammopathy Non-opposition formulated

        Exclusion Criteria:

        Minor patient Major protected Patient with another haemopathy secreting a monoclonal
        immunoglobulin (lymphoma, LLC ...) Physical or mental incapacity Refusal to participe
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Emilie BRENAUT</last_name>
    <phone>02-98-22-33-15</phone>
    <email>emilie.brenaut@chu-brest.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean-Richard Eveillard</last_name>
    <email>jean-richard.eveillard@chu-brest.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHRU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilie BRENAUT</last_name>
      <email>emilie.brenaut@chu-brest.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 5, 2019</study_first_submitted>
  <study_first_submitted_qc>February 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2019</study_first_posted>
  <last_update_submitted>July 18, 2019</last_update_submitted>
  <last_update_submitted_qc>July 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paraproteinemias</mesh_term>
    <mesh_term>Monoclonal Gammopathy of Undetermined Significance</mesh_term>
    <mesh_term>Pruritus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All collected data that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Data will be available after the publication of result and ending three years maximum following the last visit of the last patient</ipd_time_frame>
    <ipd_access_criteria>Data access requests will be reviewed by the internal committee of Brest UH. requestors will be required to sign and complete a data access agreement</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

